More recently, a trial using MSCs to minimize localized inflammation in response to one‐way endobronchial valve insertion in patients with COPD showed similar reductions in circulating CRP between 1 and 3 months after treatment.9 The gene discussed is CRP; the disease is chronic obstructive pulmonary disease.